Current evidence implies that TNF-α antagonists may ease arterial stiffness in RA.107 A substantial proportion of work-disabled patients with RA who start anti-TNF therapy regain work ability.108 Compared with patients with RA receiving sDMARD therapy, TNFi can decrease the risk of myocardial infarction.109 In the last 15 years, knowledge on the efficacy and toxicity of the TNFi has been published and was mainly gathered through regional or national registries created after these drugs reach the market. This evidence concerns the gene TNF and myocardial infarction.